Vaxart Revenue Jumps 520% in Fiscal Q2
(OTC:VXRT), a biotechnology company focused on developing oral tablet vaccines for infectious diseases, reported its second quarter results on August 13, 2025. The standout headline was a revenue surge to $39.7 million (GAAP)—well above the $2.03 million analyst consensus—driven by a step-up in government contract income, mainly from the Biomedical Advanced Research and Development Authority (BARDA). Earnings per share loss (GAAP) narrowed to $0.07, ahead of the $0.09 GAAP loss expected by analysts. While the topline performance (GAAP) easily surpassed expectations thanks to BARDA funding for its COVID-19 pill vaccine program, the period was marked by sharply rising research costs, government-mandated pauses in the key COVID-19 trial, and persistent questions around future funding and regulatory progress. Overall, the quarter saw financial outperformance and advances in clinical trials, but also greater operational and strategic uncertainty given escalating expenses and reliance on external partnerships.
Source: Analyst estimates for the quarter provided by FactSet.
Vaxart is building a portfolio of oral vaccines designed to address infectious diseases including norovirus, COVID-19, and influenza. Its lead programs target major public health threats and aim to differentiate with tablet-based delivery that avoids injections. The company’s proprietary platform allows vaccines to be delivered as pills, which could improve convenience, increase uptake, and reach populations needing needle-free solutions.
Source Fool.com
